Evidence map›Paper›PMID 38844533›Full record

ArticleMolecular psychiatry2024

Inhibition of post-lanosterol biosynthesis by fentanyl: potential implications for Fetal Fentanyl Syndrome (FFS).

Zeljka Korade, Allison C Anderson, Kanika Sharma, Keri A Tallman, Hye-Young H Kim, Ned A Porter, Karen W Gripp, Karoly Mirnics

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Sterol biosynthesis, brain development, and disease.The Journal of clinical investigation · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zeljka KoradeDepartment of Pediatrics, Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA.ORCID 0000-0002-8690-4507
Allison C AndersonMunroe-Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center, Omaha, NE, 68198, USA.ORCID 0000-0002-3511-939X
Kanika SharmaMass Spectrometry Core, University of Nebraska Medical Center, Omaha, NE, 68198, USA.ORCID 0009-0002-8754-9655
Keri A TallmanDepartment of Chemistry, Vanderbilt Institute of Chemical Biology and Vanderbilt Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, TN, 37240, USA.
Hye-Young H KimDepartment of Chemistry, Vanderbilt Institute of Chemical Biology and Vanderbilt Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, TN, 37240, USA.
Ned A PorterDepartment of Chemistry, Vanderbilt Institute of Chemical Biology and Vanderbilt Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, TN, 37240, USA.
Karen W GrippDivision of Medical Genetics, Nemours Children's Hospital, Wilmington, DE, 19803, USA.ORCID 0000-0001-8200-1733
Karoly MirnicsMunroe-Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center, Omaha, NE, 68198, USA. karoly.mirnics@unmc.edu.ORCID 0000-0002-5521-0254

Funding

Neocortical Transcriptome Changes in SchizophreniaR01MH067234 · NIMH · VANDERBILT UNIVERSITY · PI MIRNICS, KAROLY · 2003 to 2021
$4.7M
SLOS and Neuronal Oxidative StressR01HD064727 · NICHD · VANDERBILT UNIVERSITY · PI PORTER, NED ALLEN · 2010 to 2020
$3.7M
Vulnerability of DHCR7+/- mutation carriers to aripiprazole and trazodone treatmentR01MH110636 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI MIRNICS, KAROLY, PORTER, NED ALLEN · 2017 to 2021
$2.7M
Reversing disrupted developmental sterol biosynthesis by prescription medicationsR56HD111119 · NICHD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KORADE, ZELJKA, MIRNICS, KAROLY · 2024 to 2024
$230k
NICHD NIH HHS R01 HD064727NICHD NIH HHS R56 HD111119NIMH NIH HHS R01 MH067234NIMH NIH HHS R01 MH110636U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH110636
6 · The paper itself

Abstract

A recent study discovered a novel, complex developmental disability syndrome, most likely caused by maternal fentanyl use disorder. This Fetal Fentanyl Syndrome (FFS) is biochemically characterized by elevated 7-dehydrocholesterol (7-DHC) levels in neonates, raising the question if fentanyl inhibition of the dehydrocholesterol reductase 7 (DHCR7) enzyme is causal for the emergence of the pathophysiology and phenotypic features of FFS. To test this hypothesis, we undertook a series of experiments on Neuro2a cells, primary mouse neuronal and astrocytic cultures, and human dermal fibroblasts (HDFs) with DHCR7

Indexed as

DehydrocholesterolsFentanylFibroblastsLanosterolOxidoreductases Acting on CH-CH Group DonorsAnalgesics, OpioidAnimalsDesmosterolFemaleFetusHumansMiceNeuronsOpioid-Related DisordersPregnancySterols7-dehydrocholesterol7-dehydrocholesterol reductaseAnalgesics, OpioidDehydrocholesterolsDesmosterolFentanylLanosterolOxidoreductases Acting on CH-CH Group DonorsSterols

Identifiers

PMID38844533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.